Barclays’s Dogwood Therapeutics DWTX Stock Holding History

Barclays’s Portfolio DWTX Stock Details DWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5	Closed	-$39	–	5801
2025 Q3	$39	Buy	+5	New	+$25	﹤0.01%	5329

Other funds holding DWTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Barclays's DWTX Position: Q4 2025 in Review

Barclays sold out of Dogwood Therapeutics (DWTX) in Q4 2025, closing a stake of 5 shares — an estimated $39 sold.

Barclays first reported a position in DWTX in Q3 2025 and held it in 1 quarter. The position peaked at $39 in Q3 2025. 10 funds tracked by Wall St. Rank hold DWTX as of Q4 2025.

Barclays reported no remaining Dogwood Therapeutics position as of Q4 2025 after selling out during the quarter.
Barclays sold 5 Dogwood Therapeutics shares in Q4 2025, an estimated $39.
Barclays first reported a position in Dogwood Therapeutics in Q3 2025 and held it in 1 quarter.
Barclays's Dogwood Therapeutics position peaked at $39 in Q3 2025.
10 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.